Reaction
Cholangitis Acute reporting signals
As of the last recalculation, Cholangitis Acute appears in 724 FAERS reports alongside 12 co-occurring drug terms. The strongest observed disproportionality signal is URSODIOL (PRR 32.7).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Ursodiol | 24 | 32.7 | 32.8 |
| Durvalumab | 19 | 27.5 | 27.6 |
| Ursosiol | 18 | 27.3 | 27.3 |
| Lenvatinib | 27 | 24.5 | 24.6 |
| Gemcitabine Hydrochloride | 38 | 21.7 | 21.7 |
| Gemcitabine | 28 | 21.2 | 21.2 |
| Trifluridine And Tipiracil | 7 | 18.9 | 18.9 |
| Lanreotide Acetate | 4 | 14.7 | 14.7 |
| Atezolizumab | 19 | 14.4 | 14.4 |
| Tolvaptan | 5 | 10.0 | 10.0 |
| Nivolumab | 29 | 8.9 | 8.9 |
| Suvorexant | 4 | 8.9 | 8.9 |